NCT05261074 (COCE) is a clinical trial of No intervention in Foreign Body Ingestion, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT05261074?

NCT05261074 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT05261074?

Interventions in NCT05261074: No intervention.

What condition does NCT05261074 study?

NCT05261074 studies Foreign Body Ingestion.

Is NCT05261074 still recruiting?

NCT05261074 is currently status unknown. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT05261074: COCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Foreign Body Ingestion During COVID-19 Lockdown

Status unknown Last updated 2 March 2022

What this trial tests

trial testing No intervention in Foreign Body Ingestion in 100 participants. Status unknown.

Timeline

20 October 2021

Primary endpoint
20 October 2022

20 October 2022

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	20 October 2021
Primary completion	20 October 2022
Estimated completion	20 October 2022
Sites	1 location across France

Drugs / interventions tested

No intervention

Conditions studied

Foreign Body Ingestion — all drugs for Foreign Body Ingestion →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 1 Day to 15, any sex, with Foreign Body Ingestion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ingestion of foreign bodies (FB) is one of the most observed domestic accidents and a frequent reason for consultation in pediatric emergency departments (PED). In the United States, nearly 100,000 ingestions of FB have been recorded by the National Poison Data System (NPDS), which represented the 4th cause of intoxication in 2015. Ingestion of FB involves very different mechanisms in children and adult patients. Unlike adults, 98% of FB ingestions in children are accidental and involve common objects found at home environment. Ingested FBs are of many types and vary depending on the object composition of the child's environment and supervision. The lockdown for COVID-19 pandemic highly modified children environment and parent supervision. Children remained at home and parents lived at home for teleworking. In this study, the modifications of children environment that could affect epidemiology of FB ingestion will be evaluated. This is a retrospective study with a sample of around \> 100 children of Louis Mourier hospital from January 1 to December 31, 2019 and from March 1 to May 31, 2020. The total duration of the study is planned for 10 months. Primary outcomes: • To determine the role of COVID-19 pandemic linked containment on the prevalence of FB ingestions in children. Secondary outcomes: * Describe the epidemiological-clinical, radiological, therapeutic and evolutionary characteristics of the FB consultant's ingestions in the emergency department * Determine the frequency of endoscopy or surgery * Determine the factors favoring the use of endoscopic extraction From March 16 to May 10, 2020.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05261074 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05261074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing